Clinical Trial SuccessPlozasiran achieved consistent, durable, statistically significant placebo-adjusted median reductions in fasting triglycerides compared to baseline, meeting the trial's primary endpoint.
Drug Development PotentialPlozasiran treatment led to a statistically significant reduction in incidence of acute pancreatitis versus placebo, supporting its best-in-class potential in familial chylomicronemia syndrome.
Pipeline ExpansionArrowhead's highly underappreciated pulmonary pipeline continues to advance as a clear leader in the RNA therapeutics space and may soon unlock substantial value for shareholders.